GlassScriptPhysician profile
Milton D Moore, JR.
NPI 1518030113
$5,582.49
in general payments reported to CMS, 2019-2025
29 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $233 · 2021: $674 · 2022: $1,838 · 2023: $1,440 · 2024: $456 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,982 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,982.26 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,025.75 | 2020-2023 | |
| Sun Pharmaceutical Industries INC. | $585.39 | 2021-2025 | Winlevi, Absorica Ld |
| Pfizer INC. | $459.65 | 2019-2023 | |
| Genzyme Corporation | $443.01 | 2021-2023 | |
| Amgen INC. | $424.94 | 2019-2023 | Otezla |
| Galderma Laboratories, L.P. | $354.24 | 2019-2024 | |
| Incyte Corporation | $330.02 | 2022-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $308.71 | 2022-2023 | Sotyktu |
| Leo Pharma INC. | $242.75 | 2019-2023 | Adbry |
| Revance Therapeutics, INC. | $182.93 | 2024 | Daxxify |
| Allergan, INC. | $143.96 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $137.81 | 2019-2021 | |
| Janssen Biotech, INC. | $134.69 | 2019-2024 | Tremfya |
| Janssen Scientific Affairs, LLC | $124.98 | 2019 | |
| Abbott Laboratories | $121.71 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $105.53 | 2023 | |
| Lilly USA, LLC | $89.05 | 2023-2025 | Ebglyss, Olumiant, Taltz |
| Merz North America, INC. | $57.64 | 2024 | |
| Sebela Pharmaceuticals INC. | $53.46 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $43.65 | 2022 | |
| Arcutis Biotherapeutics, INC. | $41.17 | 2024 | Zoryve |
| Medimetriks Pharmaceuticals, INC. | $32.20 | 2022-2023 | |
| Novo Nordisk INC | $24.89 | 2023 | Rybelsus |
| Dermira, INC. | $24.88 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $21.03 | 2024 | |
| Glenmark Therapeutics INC. | $20.00 | 2019 | |
| Celgene Corporation | $19.77 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $16.17 | 2019 | |
| Journey Medical Corporation | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milton Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.